Evaluation of Safety and Efficacy of Intravenous Digoxin Loading Doses Based on Ideal Body Weight

被引:2
|
作者
Clark, Jessi L. [1 ,2 ,6 ]
Jacobs, Joshua A. [1 ,3 ]
Watanabe, Alexandre H. [4 ]
Catino, Anna B. [5 ]
Dechand, John A. [1 ]
机构
[1] Univ Utah Hlth, Dept Pharm, Salt Lake City, UT 84102 USA
[2] Univ Kentucky HealthCare, Dept Pharm, Lexington, KY 40536 USA
[3] Univ Utah, Dept Populat Hlth Sci, Salt Lake City, UT 84112 USA
[4] Univ Utah, Coll Pharm, Salt Lake City, UT 84112 USA
[5] Univ Utah Hlth, Dept Cardiol, Salt Lake City, UT 84102 USA
[6] Univ Kentucky HealthCare, Dept Pharm, 1000 S Limestone, Room H110A, Lexington, KY 40536 USA
关键词
digoxin; drug monitoring; dose-response relationship; arrhythmias; dosing; ATRIAL-FIBRILLATION; INCREASED MORTALITY; RISK;
D O I
10.1177/10600280221146530
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background: Intravenous digoxin loading dose recommendations differ between clinical guidelines and Food and Drug Administration packaging for acute rate control. Objective: The objective of this study was to assess the safety and efficacy of intravenous digoxin loading in patients who received <= 12 mu g/kg and >12 mu g/kg of digoxin using ideal body weight (IBW). Methods: This single center retrospective cohort study with exempt status from the local Institutional Review Board included patients who received intravenous digoxin and had a serum digoxin concentration (SDC) drawn. Digoxin doses >36 hours after the first dose were excluded. Patients who received a total of >12 mu g/kg and <= 12 mu g/kg IBW were compared. The primary endpoint was frequency of SDCs >= 1.2 ng/mL, which have been shown to be associated with increased mortality. Results: A total of 244 patients were included (144 receiving >12 mu g/kg and 100 receiving <= 12 mu g/kg). There were significantly more SDC >= 1.2 ng/mL in the >12 mu g/kg group than the <= 12 mu g/kg group (50.6% vs. 30.0%; adjusted odds ratio, 3.19; 95% confidence interval [CI]: 1.79-5.84), with no difference in rate control failure. Major limitations of the study include retrospective nature and possible selection bias. Conclusion and Relevance: Compared to patients who received digoxin doses <= 12 mu g/kg IBW, patients who received >12 mu g/kg IBW had higher rates of SDC >= 1.2 ng/mL. This suggests that appropriate weight-based dosing with 8 to 12 mu g/kg IBW has the potential to be a safer approach to digoxin loading, rather than frequently used dosing strategies that result in doses >12 mu g/kg.
引用
收藏
页码:1154 / 1161
页数:8
相关论文
共 23 条
  • [1] Evaluation of Intravenous Phenytoin and Fosphenytoin Loading Doses: Influence of Obesity and Sex
    DasGupta, Ryan
    Alaniz, Cesar
    Burghardt, Danielle
    ANNALS OF PHARMACOTHERAPY, 2019, 53 (05) : 458 - 463
  • [2] Safety and Efficacy of Loading Doses of Vitamin D: Recommendations for Effective Repletion
    Toth, Bela E.
    Takacs, Istvan
    Kadar, Kristof
    Mirani, Sara
    Vecsernyes, Miklos
    Lakatos, Peter
    PHARMACEUTICALS, 2024, 17 (12)
  • [3] Efficacy and safety of factor Xa inhibitors in low body weight patients
    Tan, Yingcong
    Hubbard, Cynthia
    Owens, Holly
    Pitt, James
    Giuliano, Christopher
    Haan, Bradley
    Breeden, Thomas
    Sirbu, Dumitru
    Pena, Kelsey
    Haddox, Trevlyn
    Edwin, Stephanie B.
    PHARMACOTHERAPY, 2024, 44 (02): : 131 - 140
  • [4] Safety and efficacy of lenvatinib by starting dose based on body weight in patients with unresectable hepatocellular carcinoma in REFLECT
    Okusaka, Takuji
    Ikeda, Kenji
    Kudo, Masatoshi
    Finn, Richard
    Qin, Shukui
    Han, Kwang-Hyub
    Cheng, Ann-Lii
    Piscaglia, Fabio
    Kobayashi, Masahiro
    Sung, Max
    Chen, Minshan
    Wyrwicz, Lucjan
    Yoon, Jung-Hwan
    Ren, Zhenggang
    Mody, Kalgi
    Dutcus, Corina
    Tamai, Toshiyuki
    Ren, Min
    Hayato, Seiichi
    Kumada, Hiromitsu
    JOURNAL OF GASTROENTEROLOGY, 2021, 56 (06) : 570 - 580
  • [5] Safety and efficacy of lenvatinib by starting dose based on body weight in patients with unresectable hepatocellular carcinoma in REFLECT
    Takuji Okusaka
    Kenji Ikeda
    Masatoshi Kudo
    Richard Finn
    Shukui Qin
    Kwang-Hyub Han
    Ann-Lii Cheng
    Fabio Piscaglia
    Masahiro Kobayashi
    Max Sung
    Minshan Chen
    Lucjan Wyrwicz
    Jung-Hwan Yoon
    Zhenggang Ren
    Kalgi Mody
    Corina Dutcus
    Toshiyuki Tamai
    Min Ren
    Seiichi Hayato
    Hiromitsu Kumada
    Journal of Gastroenterology, 2021, 56 : 570 - 580
  • [6] Anticoagulation and BMI: effect of high body weight on the safety and efficacy of direct oral anticoagulants
    Mausteller, Kyle G.
    Eisele, Caroline D.
    Julian, Katherine
    Patel, Puja
    Bansal, Amit
    Jain, Rahul
    Jain, Rohit
    FUTURE CARDIOLOGY, 2022, 18 (10) : 829 - 837
  • [7] Efficacy of nivolumab four-weekly dosing schedule based on body weight
    de Lemos, Mario L.
    Kung, Carrie
    Waignein, Sally
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2019, 25 (04) : 961 - 963
  • [8] Efficacy and Safety of Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Extremes in Body Weight Insights From the ARISTOTLE Trial
    Hohnloser, Stefan H.
    Fudim, Marat
    Alexander, John H.
    Wojdyla, Daniel M.
    Ezekowitz, Justin A.
    Hanna, Michael
    Atar, Dan
    Hijazi, Ziad
    Cecilia Bahit, M.
    Al-Khatib, Sana M.
    Luis Lopez-Sendon, Jose
    Wallentin, Lars
    Granger, Christopher B.
    Lopes, Renato D.
    CIRCULATION, 2019, 139 (20) : 2292 - 2300
  • [9] Safety and Efficacy of Prasugrel in Elderly/Low Body Weight Japanese Patients with Ischemic Stroke: Randomized PRASTRO-II
    Kitagawa, Kazuo
    Toyoda, Kazunori
    Kitazono, Takanari
    Nishikawa, Masakatsu
    Nanto, Shinsuke
    Ikeda, Yasuo
    Abe, Kenji
    Ogawa, Akira
    CEREBROVASCULAR DISEASES, 2020, 49 (02) : 152 - 159
  • [10] Effects of the concomitant administration of tamsulosin (0•8 mg) on the pharmacokinetic and safety profile of intravenous digoxin (Lanoxin®) in normal healthy subjects:: a placebo-controlled evaluation
    Miyazawa, Y
    Starkey, LP
    Forrest, A
    Schentag, JJ
    Kamimura, H
    Swarz, H
    Ito, Y
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2002, 27 (01) : 13 - 19